Autoantibodies against oxidised low-density lipoprotein were significantly increased in patients with obstructive sleep apnoea compared to controls (p = 0.001).
Cross-Sectional (n=351)
Are autoantibodies against oxidised low-density lipoprotein (OxLDL-Abs) elevated in patients with obstructive sleep apnoea compared to controls?
Although OxLDL-Abs are elevated in patients with obstructive sleep apnoea, they do not correlate with traditional cardiovascular risk factors, suggesting the biomarker is not currently applicable for clinical screening in this population.
p-value: p=0.001
Autoantibodies against oxidised low-density lipoprotein (OxLDL-Abs) have been proposed to be an indicator of endothelial dysfunction and a novel tool for finding individuals with a high cardiovascular risk. In a cross-sectional study, OxLDL-Abs were measured in 297 patients with obstructive sleep apnoea (OSA) and 54 controls using an enzyme-linked immunosorbent assay. The autoantibodies were increased in patients with OSA when compared to controls (age, body mass index (BMI) and gender adjusted, p = 0.001). However, within the OSA patients, OxLDL-Abs were not related to smoking, hypertension or BMI, and there was a weak negative correlation (r = -0.16, P = 0.007) between age and levels of OxLDL-Abs. In conclusion, at present the measurement OxLDL-Abs still remains a method for basic research and is not applicable for screening of at-risk patients with OSA.
Saarelainen et al. (Sat,) conducted a cross-sectional in obstructive sleep apnoea (n=351). Autoantibodies against oxidised low-density lipoprotein (OxLDL-Abs) vs. Controls was evaluated on OxLDL-Abs levels (p=0.001). Autoantibodies against oxidised low-density lipoprotein were significantly increased in patients with obstructive sleep apnoea compared to controls (p = 0.001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: